Top in cardiology: Omega-3 fatty acid supplementation, hypertension guidance

Study findings suggest that omega-3 fatty acid supplementation may increase the risk for atrial fibrillation in certain high-risk patients. This discovery was the top story in cardiology last week.

Another top story was about an update to the American Heart Association’s hypertension guidance. The organization recommends lifestyle therapy as a primary treatment for patients with stage 1 hypertension followed by medication if the patient does not see results after 6 months.

Read these and more top stories in cardiology below:

Omega-3 fatty acid supplementation may increase AF odds in certain high-risk patients

Omega-3 fatty acid supplementation was associated with elevated risk for atrial fibrillation among patients with elevated triglyceride levels at high CV risk, researchers reported. Read more.

In stage 1 hypertension, medication feasible if BP goal not met after lifestyle changes

In an update to the 2017 hypertension guideline, the American Heart Association recommended lifestyle changes for patients with slightly elevated BP, adding medication if necessary after 6 months. Read more.

Atypical MI symptoms tied to negative outcomes, lower odds of emergency response

Patients with atypical MI symptoms were less likely to receive emergency help and had greater risk for dying within 30 days compared with those with chest pain, researchers reported. Read more.

Elevated maternal lipids associated with development of gestational diabetes

Elevated maternal lipids, especially elevated levels of triglycerides, were associated with the development of gestational diabetes, according to new results from a systematic review and meta-analysis. Read more.

Low bone mineral density predictor of ASCVD in women

Evaluating bone mineral density can help predict atherosclerotic CVD events in women, according to a study published in Heart. Read more.